1-3 of 3
Carol Ann Huff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal

Christian B. Gocke, Ross McMillan, Qiuju Wang, Asma Begum, Vesselin R. Penchev, Syed A. Ali, Ivan Borrello, Carol Ann Huff, William Matsui
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2733–2739.
https://doi.org/10.1158/1535-7163.MCT-16-0323
Published: 01 November 2016
View articletitled, IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal
Open the PDF for IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal in another window
Includes: Supplementary data
Journal Articles

Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma

Jasmin R. Agarwal, Qiuju Wang, Toshihiko Tanno, Zeshaan Rasheed, Akil Merchant, Nilanjan Ghosh, Ivan Borrello, Carol Ann Huff, Farhad Parhami, William Matsui
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (7): 1873–1881.
https://doi.org/10.1158/1535-7163.MCT-13-0997
Published: 06 July 2014
View articletitled, Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma
Open the PDF for Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

The novel telomerase inhibitor GRN163L targets drug-resistant cancer stem cells in multiple myeloma

William Matsui, Qiuju Wang, Sarah Brennan, Alan Meeker, Robert Tressler, Calvin Harley, Carol Ann Huff, B. Douglas Smith, Richard Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A97.
Published: 01 November 2007
View articletitled, The novel telomerase inhibitor GRN163L targets drug-resistant cancer stem cells in multiple myeloma